REVIEW

Recent advances in understanding dengue [version 1; peer review: 2 approved]

Scott Halstead

Emeritus Professor, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA

V1 First published: 31 Jul 2019, 8(F1000 Faculty Rev):1279
<https://doi.org/10.12688/f1000research.19197.1>

Latest published: 31 Jul 2019, 8(F1000 Faculty Rev):1279
<https://doi.org/10.12688/f1000research.19197.1>

Abstract

This is a selective review of recent publications on dengue clinical features, epidemiology, pathogenesis, and vaccine development placed in a context of observations made over the past half century. Four dengue viruses (DENVs) are transmitted by urban cycle mosquitoes causing diseases whose nature and severity are influenced by interacting factors such as virus, age, immune status of the host, and human genetic variability. A phenomenon that controls the kinetics of DENV infection, antibody-dependent enhancement, best explains the correlation of the vascular permeability syndrome with second heterotypic DENV infections and infection in the presence of passively acquired antibodies. Based on growing evidence *in vivo* and *in vitro*, the tissue-damaging DENV non-structural protein 1 (NS1) is responsible for most of the pathophysiological features of severe dengue. This review considers the contribution of hemophagocytic histiocytosis syndrome to cases of severe dengue, the role of movement of humans in dengue epidemiology, and modeling and planning control programs and describes a country-wide survey for dengue infections in Bangladesh and efforts to learn what controls the clinical outcome of dengue infections. Progress and problems with three tetravalent live-attenuated vaccines are reviewed. Several research mysteries remain: why is the risk of severe disease during second heterotypic DENV infection so low, why is the onset of vascular permeability correlated with defervescence, and what are the crucial components of protective immunity?

Keywords

dengue, flavivirus, pathogenesis, immunity, dengue fever, severe dengue, vaccines, epidemiology

Open Peer Review

Approval Status

	1	2
version 1
31 Jul 2019		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Aravinda M de Silva**, University of North Carolina School of Medicine, Chapel Hill, USA
2. **Subhash G Vasudevan**, Duke-NUS Medical School, Singapore, Singapore

Any comments on the article can be found at the end of the article.

Corresponding author: Scott Halstead (halsteads@erols.com)

Author roles: Halstead S: Writing – Original Draft Preparation

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2019 Halstead S. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Halstead S. **Recent advances in understanding dengue [version 1; peer review: 2 approved]** F1000Research 2019, 8(F1000 Faculty Rev):1279 <https://doi.org/10.12688/f1000research.19197.1>

First published: 31 Jul 2019, 8(F1000 Faculty Rev):1279 <https://doi.org/10.12688/f1000research.19197.1>

Introduction

Dengue viruses (DENVs) are relatively new pathogens. Transmission of virus from human to human by the bite of the mosquito *Aedes aegypti* began around three centuries ago^{1,2}. Establishing an urban cycle required three separate emergence events: (a) evolution of a West African tree hole-breeding ancestor into *Aedes aegypti*, an anthropophilic domestic-breeding sub-species, and transportation of this mosquito (b) to tropical America via the slave trade and (c) in reverse direction to Europe and Asia where each of the four DENVs were introduced into the urban transmission cycle^{3,4}. These emergence events in all likelihood were preceded by the circulation of a parental virus in sub-human primates throughout greater Southeast Asia during the Quaternary ice age⁵. Oceans rose to isolate populations of dengue-infected sub-human primates on mainland Asia and on the islands of Indonesia and the Philippines⁶. Viral evolution did the rest. Now these viruses cause a global pandemic, a consequence of jet airplane distribution of viremic humans throughout a tropical world comprehensively infested by *Aedes aegypti*^{7,8}.

The world of dengue is massive and its features are constantly changing, as evidenced by the expanding scientific literature. Studies on dengue as an arthropod-borne viral disease contribute to three areas of research: (a) one on mosquito vectors, their bionomics, virus–host interactions, epidemiology, and control; (b) a literature on the virus itself; and (c) another describing DENV–human interactions. This review is directed to the last of these, focusing on clinical features, epidemiology, pathogenesis, and vaccine development.

The four DENVs are genetically related and biologically similar. Dengue is not the only human viral pathogen to circulate in biologically or genetically related groups. Many enteroviruses and respiratory viruses exist in groups of closely related pathogens. Although some degree of cross-protection may accompany sequential infections with members of these groups, most such outcomes are not well studied or understood. Dengue differs for researchers, a clear-eyed view of the observed complexity of dengue 1, 2, 3, and 4 (DENV) interactions with humans is crucial. For details of dengue disease features and pathogenesis, see my previous F1000 report⁹. Infection with a single virus is followed by up to three outcomes: (1) durable protection against infection with a strain of the same DENV, (2) brief protection against infection or disease with a different dengue serotype, and (3) a breakthrough infection with a different dengue serotype that may result in severe disease^{10–12}. This last outcome has a unique variant: dengue infection in the presence of passively acquired multitypic dengue antibodies may produce severe disease¹³. Severe dengue in infants born to dengue-immune mothers is an important problem where dengue is highly endemic, causing 5% of dengue hospitalizations of children^{14–17}.

Clinical responses

Dengue clinical responses are subject to constraints imposed by infecting virus, epidemiology, human immune status, and human genetic makeup. These are reviewed briefly. Dengue disease severity differs by infection parity. Disease may accompany a first

or second dengue infection and is infrequent during a third and absent during a fourth^{18–20}.

First infections

Intuitively, infection should result in a dengue clinical outcome. This is far from being the case. Age and viral type have an impact. In young children, primary dengue 1–4 infections are frequently inapparent^{21–24}. As children age, disease response, particularly after puberty, becomes more adult-like. The infecting dengue type interacting with age also controls disease severity. In adults, primary dengue 1 and 3 infections result in high rates of classic dengue fever but dengue 2 and 4 infections cause milder disease and are often inapparent^{12,25}. Primary dengue 2 and 4 infections in children of all ages frequently are inapparent^{24,26}. Primary dengue 1 infections in children are modestly severe to the point of requiring hospitalization²⁶.

Second infections

Second heterotypic dengue disease has been observed in 12 sequences¹⁹. In children, overt disease is recognized clinically in perhaps 20 to 30% of second heterotypic dengue infections and severe disease in about 2%^{12,27,28}. A high incidence of severe disease has been reported for infection sequences with DENV1–2, 3–2, 4–2, 1–3, and 2–1^{27,29–32}. The severity of second heterotypic dengue infections is controlled by age at the time of infection and the interval between first and second infections. Owing to their intrinsic risk of severe vascular permeability, young children are at higher risk of fatal outcome with heterotypic DENV infections³³. Exposure to DENV at intervals of less than 2 years may inhibit infection and suppress disease severity^{19,34}. Short-term protection and ultimately enhanced second heterotypic DENV infection outcome may be controlled by natural declines or changes in heterotypic antibodies (or both) following a first DENV infection^{35,36}. An increase in disease severity was observed when the interval between first and second infections was 20 years as opposed to 4 years³⁰. As an explanation, it was observed that severe disease at a long interval was correlated with an observed steady decrease in heterotypic antibody titers over a long period^{37,38}. During secondary dengue infections, adults are at greater risk than children of bleeding whereas children are at greater risk than adults of vascular permeability³⁹. Human genetic inhomogeneity, particularly across ethnic groups, affects disease expression in a variety of ways^{40–43}. The most notable genetic effect is the suppression of severe disease accompanying a second heterotypic dengue infection that has been observed in black patients in sub-Saharan Africa and is linked to a gene that regulates cellular dengue infection via lipid metabolism⁴⁴. A final pathophysiological constraint during secondary dengue infection is the fact that the onset of vascular permeability is correlated with defervescence. Mechanisms controlling these constraints are not well understood.

Despite a consensus on the importance of early recognition of the remediable dengue vascular permeability syndrome (DVPS) (fever, thrombocytopenia, abnormal hemostasis, elevated liver enzyme levels, hypoalbuminemia, complement activation, and vascular permeability), there is not wide agreement about how

to define dengue disease⁴⁵. “Severe dengue” may include life-threatening conditions such as severe bleeding or impaired central nervous system, heart, or kidney functions in the absence of vascular permeability. This wide range of poorly defined and diverse pathophysiological endpoints may impede the early recognition and rapid and accurate assessment of fluid losses to be followed by accurate management of fluid resuscitation. Critically, research to identify pathophysiological mechanisms of the vascular permeability syndrome requires relevant and standardized case definitions⁴⁶.

A literature describing unusual clinical features or outcomes of dengue infections continues to grow at a record pace fueled by the hundreds of thousands of dengue cases that present yearly to sophisticated health-care systems. It is often difficult to place these cases into a pathogenic context because of missing viral, immunological, or epidemiological details (see above). Needed are virus type, age and sex of patients, and infection parity (for example, IgM/IgG ratio) and, if there is a second heterotypic infection, evidence concerning the interval between first and second infections and the identity of first infecting DENV type.

A subset of severe dengue cases, hemophagocytic lymphohistiocytosis (HLH), is increasingly recognized. HLH, a rare and potentially fatal disorder associated with acute infections, is characterized by fever, pancytopenia, hepatosplenomegaly, and increased serum ferritin. In Puerto Rico, 22 dengue HLH cases, including one death, were detected from 2008 to 2013. Cases were often infants, who frequently had influenza co-infections and were satisfactorily treated with steroids⁴⁷. There have been a number of individual case reports of HLH, predominantly from Asia⁴⁸. Many of these occurred after prolonged fever⁴⁹. An early diagnosis of HLH could deflect from a careful search for vascular permeability and promote the premature use of steroids that have been widely but ineffectively used to treat vascular permeability shock syndrome⁵⁰.

Thrombocytopenia accompanies many dengue infections. The widely used term “dengue hemorrhagic fever” has sensitized doctors and patients alike to the possibility that severe life-threatening bleeding may occur without warning. For this reason, low platelet counts are widely considered to be an indication for the prophylactic administration of platelets. Clinical experts have uniformly advocated against this expensive and potentially dangerous practice^{51–54}. Investigators in Singapore and Malaysia conducted an open-label, randomized, superiority trial of platelet transfusion and enrolled 372 persons (21 years old or older) with acute laboratory-confirmed dengue with thrombocytopenia (not more than 20,000 platelets per microliter) but no severe or persistent mild bleeding. After enrollment, the subsequent frequency of clinical bleeding was slightly higher (26%) in the transfusion group, 13 of whom had adverse events, than in controls. No deaths were reported⁵⁵.

Progress is being made in identifying and interpreting physiological signals in patients who may progress to shock syndrome. A low echocardiographic stroke volume index and reduced left ventricular function plus high admission venous lactate

levels identified dengue patients at high risk of recurrent shock and respiratory distress⁵⁶. In 2000, age of 5 to 15 years, a history of vomiting, higher temperature, a palpable liver, and a lower platelet count were risk factors for dengue shock while, during illness, absolute values and rate of daily decline of platelet counts successfully predicted shock⁵⁷.

Epidemiology

During yellow fever epidemics, it was well understood that multiple cases occurred among members of households but also in persons who visited infested homes. Though less obviously, this same epidemiological feature applies to dengue. Careful prospective studies in the city of Iquitos on the Amazon River in Peru successfully tracked household members throughout the city during DENV transmission seasons⁵⁸. For individuals, the risk of DENV infection is controlled by the presence or absence of *Aedes aegypti* in places visited during the daytime. Risk is not a matter of vector abundance but of vector presence. Individuals increased their estimated transmission rate from 1.3 if they stayed at home to 3.75 when they visited other locations during daytime hours (for example, markets or homes of friends or relatives)⁵⁹. DENV is not spread significantly by sick individuals. Those who developed dengue fever spent more time at home, visited fewer locations, and in some cases visited locations closer to home and spent less time at certain types of locations than did individuals who were well⁶⁰.

In highly endemic southern Vietnam and Yogyakarta, a city in Indonesia, mobility data collected from children and young adults via prospective travel diaries found that all ages spent about half of their daytime hours (5 a.m. to 9 p.m.) at home while children under the age of 14 years spent a greater proportion of their time within 500 m of home than did older respondents. Mobility of specific age groups within populations must be taken into consideration in planning dengue preventive interventions^{61,62}.

There is now better understanding of how DENVs successfully maintain transmission when only 20 to 30% of infected persons develop a disease. Studies indicate that silent infections may contribute as much as 84% of total DENV transmission. In persons who do develop dengue disease, most infections of mosquitoes occur prior to the onset of symptoms and only 1% of mosquito infections occur after symptoms have begun⁶³. The substantial role that inapparent infections play during dengue epidemics may contribute to more rapid transmission and widespread geographic spread of virus, reducing the usefulness of case data to predict where an outbreak will occur and what its final size will be^{64,65}.

The introduction of a new flavivirus, Zika, into the Western Hemisphere in 2015 was the cause of considerable consternation, not simply because of its unexpected linkage to Guillain-Barré syndrome; Zika infection of pregnant women also caused a congenital Zika syndrome in infants. There were additional fears that Zika infections might enhance DENV infections or vice versa. An entirely unsuspected outcome has been that Zika behaves like a highly effective dengue vaccine. The Zika

epidemic of 2015 to 2016 was followed by a reduction in clinical dengue cases throughout Latin America from 2,413,693 in 2015 to about 500,000 in both 2017 and 2018, a 77% reduction in dengue cases (Pan American Health Organization data). Similar outcomes were reported from surveillance studies in Salvador, Brazil^{66,67}. It is suspected that Zika infection may have served to protect an epidemiologically and clinically important group, monotypic dengue-immunes, responsible for secondary DENV clinical disease⁶⁸.

A mystery in the global dengue pandemic is why, in the mid-20th century, severe dengue was highly endemic in Southeast but not South Asia⁶⁹. A remarkable nationwide survey of vector mosquitoes, dengue antibodies, and clinical disease, conducted in Bangladesh, may provide an answer. Out of 97,162 total communities, 70 were randomly selected for visits in 2014 and 2016, and one sixth of households, including 5,866 individuals, were interviewed⁷⁰. Many areas of rural Bangladesh were found to be devoid of dengue disease with low prevalence of dengue antibodies and low or no populations of *Aedes aegypti* and *Aedes albopictus*. Residents of Dhaka and Chittagong, where a number of recent outbreaks of dengue and chikungunya have occurred, had a high prevalence of dengue antibodies, abundant vector mosquitoes, and disease. A cluster of smaller cities and villages in the Southwestern corner of the country had modest dengue endemicity. The epidemiology of dengue in India may have been similar to that in Bangladesh today but suffered a steady invasion of *Aedes aegypti* throughout the country and into rural areas. This epidemiological evolution may explain the recent emergence of epidemic severe dengue throughout India.

The reason why yellow fever continues to be a major health problem in the American tropics is a fateful event that occurred centuries ago: the stable introduction of yellow fever virus into a complex zoonotic cycle⁷¹. All four DENVs circulate as zoonoses in Asia and zoonotic dengue 2 was possibly transplanted from Asia to Africa. Genetic studies suggest that, during the slave trade, the African DENV2 was brought to the American tropics, where it entered the urban cycle⁵. But has a dengue zoonotic cycle been established? Only modest efforts have been made to answer this question. A search for a sylvatic DENV cycle was initiated in a forested area of the eastern Amazon near Iquitos, Peru, a city where all four DENVs are endemic. Twenty seronegative Aotus monkeys were kept in jungle locations for a total of 10 years and were bled for virus and for antibody conversions with no evidence of DENV⁷².

Pathogenesis

Soon after the DVPS was identified, clinical and epidemiological data strongly associated it with second heterotypic DENV infections and also with primary DENV infections of infants born to dengue-immune mothers^{11,73}. Pathology studies have consistently demonstrated human DENV infection target cells to be of myeloid lineage⁷⁴. When DENV infections occur *in vitro* or *in vivo* in the presence of sub-neutralizing dengue antibodies, enhanced infections/disease may result^{35,75}. Indeed, the peak of early illness viremias or antigenemia successfully predicted disease severity^{26,76,77}. This phenomenon, antibody-dependent enhancement

(ADE) of DENV infection of Fc receptor-bearing cells, differs from infection of these same cells in the absence of antibodies by two mechanisms: an increase in the number of cells infected (extrinsic ADE) or an increase in the intracellular production of DENV (intrinsic ADE)⁷⁸.

DENV ADE has been observed in animal models. Second heterotypic DENV2 infections produced enhanced viremia but not vascular permeability in rhesus monkeys⁷⁹. Efforts to reliably achieve vascular permeability disease during second heterotypic DENV infections in animals, including mice, have not been successful⁸⁰. When DENV antibodies were passively transferred to rhesus monkeys prior to infection with DENV2, enhanced viremias were observed but without vascular permeability. Administration of monoclonal or polyclonal dengue antibodies to mice has regularly resulted in enhanced DENV infections accompanied by vascular permeability and other features of DVPS⁸¹. Also, it has been possible to produce vascular permeability in DENV-infected infant mice born to dengue-immune mothers⁸². But other hypotheses of severe dengue pathogenesis that attribute disease (1) to a weakened ability of secondary T cells to contain DENV infection because of the original antigenic sin phenomenon, (2) to the hyper-production of endothelium-damaging secondary infection T-cell cytokines and chemokines, (3) to the DENV non-structural protein 1 (NS1) heterophile antibodies raised during first DENV infections that damage platelets, endothelial cells, or blood clotting proteins during second infections, or (4) to the ability of dengue IgG immune complexes to stimulate mast cells to release vasoactive amines fail to satisfy the requirements of Occam's razor^{83–86}. None of these hypotheses explains the phenomenon of infant DVPS where B- and T-cell responses are primary and anti-DENV or anti-NS1 IgG antibody concentrations at the onset of illness are absent or very low.

ADE is a kinetic force of infection but by itself is not a direct cause of pathology. Recent work in several laboratories has uncovered a pathogen that mediates DVPS with enhanced infections that occur with actively or passively acquired dengue antibodies. It was long known that fatal DENV infections of mice could be prevented by anti-NS1⁸⁷. NS1 is produced during all four DENV infections as well as those of other pathogenic flaviviruses⁸⁸. Instead of remaining cell-bound, dengue NS1 is released as a hexamer circulating in great quantities in acute-phase blood⁸⁹. A perceptive study, published in 2006, suggested that the high levels of circulating NS1 documented in patients with severe dengue might activate complement to mediate vascular permeability⁹⁰. Dengue NS1 has been shown to activate complement by the alternative pathway, target liver cells promoting intracellular DENV infection, complex with thrombin in acute-phase blood of severe dengue, activate platelets *in vitro* via Toll-like-receptor 4 (TLR4), and produce thrombocytopenia in TLR4 knockout and normal mice^{90–93}. In 2015, an analogy between the cellular biology of bacterial lipopolysaccharides (LPSs) and that of DENV NS1 was discovered⁹⁴. Each interacts with TLR4 on the surface of monocytes, macrophages, and endothelial cells, inducing the release of a range of cytokines and chemokines. Some of these same cytokines and chemokines have been found in the blood of patients accompanying DVPS. *In vitro*, NS1 disrupted

endothelial cell monolayer integrity. The authors concluded that DVPS was a viral protein toxicosis. NS1-mediated cytokine release could be inhibited by the TLR4 antagonist LPS–*Rhodobacter sphaeroides*, suggesting an avenue for therapeutic intervention.

Crucially, the same observation was confirmed in an *in vivo* model⁹⁵. DENV2 NS1 inoculated intravenously at physiologically relevant concentrations in sub-lethally DENV2-infected C57BL/6 mice resulted in lethal vascular permeability. Vaccination of mice with DENV2 NS1 protected them against endothelial leakage and death from lethal DENV2 challenge. Mice immunized with all four DENV NS1 proteins were completely protected against homologous DENV challenges, whereas immunization with DENV1 NS1 partially protected against heterologous DENV2 challenge. Furthermore, DENV NS1 was shown to directly alter the barrier function of pulmonary endothelial cell monolayers through disruption of the endothelial glycocalyx-like layer (EGL) by triggering the activation of endothelial sialidases, cathepsin L, and heparanase, enzymes responsible for degrading sialic acid and heparan sulfate proteoglycans⁹⁶. Separately, disruption of endothelial glycocalyx components had been shown to correlate with plasma leakage during severe DENV infection in humans^{97,98}. More recently, the contribution of these DENV NS1-induced endothelial cell–intrinsic pathways to NS1-mediated vascular leakage was demonstrated to be independent of inflammatory cytokines but dependent on the integrity of endothelial glycocalyx components both *in vitro* and *in vivo*⁹⁹. A DENV NS1 vaccine is taking shape¹⁰⁰. In conclusion, NS1 toxicosis is demonstrably an effluent mechanism of vascular permeability in mice and is controlled by DENV production in cells and, in turn, by ADE⁸⁸.

As described, DVPS is a rare outcome of a second heterotypic DENV infection. Identifying those at risk and understanding why they develop overt versus silent infections continue to be focuses of research. In a long-standing children's cohort in Kamphaeng Phet, Thailand, peripheral blood mononuclear cells (PBMCs) were collected from children prior to their experiencing second heterotypic DENV infections, whether overt or silent. Cultured pre-infection PBMCs were stimulated with DENV1–4 antigens. Of 30 cytokines or chemokines studied, six had elevated responses in children who experienced silent second DENV infections and three had elevated responses in children who developed symptoms during a subsequent DENV infection. Significant differences were found in cytokine production based on both the type of DENV used for stimulation and the occurrence of clinical illness. Secretion of interleukin 15 (IL-15) and monocyte chemotactic protein 1 (MCP-1) was significantly higher by PBMCs of subjects who later developed symptomatic DENV infection. These studies are beginning to show how genetic and metabolic phenomena differing between individuals may control infectious processes and host responses¹⁰¹.

Vaccines

Dengvaxia

The most advanced dengue vaccine is a chimera of structural genes of the four DENVs with the yellow fever vaccine non-structural genome. This vaccine was tested for vaccine efficacy and safety

in placebo-controlled clinical trials enrolling 35,000 children (2 to 16 years old) in 10 dengue-endemic countries¹⁰². Efficacy results were mixed. Through year 3 after the first dose, vaccine protection against hospitalization of children at least 9 years old was 65.5% but among children 8 years old or younger was 44.6%¹⁰². In the 2- to 5-year-old age group, vaccinated children were hospitalized five times more frequently than those in the placebo group. Among the 11% of children whose serostatus (when vaccinated) was known, protection in seronegative children 8 years old or younger was 14.4% but in those 9 years old or older was 52.5%. These data led the manufacturer and expert committees to recommend that vaccine be restricted to children 9 years old or older^{102,103}. A new serological test made it possible to distinguish those who were seronegative from those who were dengue-immune at the time of vaccination¹⁰⁴. When this test was applied to sera from a 10% randomized cohort of phase 3 children, dengue seronegativity rather than age controlled risk to severe hospitalized dengue disease (platelet count of less than 100,000 mm³ evidence of vascular permeability) over the period 5 to 6 years after first dose in children given vaccine¹⁰⁵. With this evidence of declining efficacy, the World Health Organization (WHO) Scientific Advisory Group of Experts, the Global Advisory Committee on Vaccine Safety, and the WHO Dengue Vaccine Working Group in 2016 recommended that vaccine be given to individuals with known past dengue infection or to populations with 80% DENV seroprevalence¹⁰⁶.

Why did Dengvaxia fail to protect seronegative children? When vaccinated children developed dengue disease despite circulating tetraivalent DENV neutralizing antibodies, this provided solid evidence that conventionally measured human neutralizing antibodies were not protective^{102,107–110}. New observations suggest that it may be necessary to redefine the design of classic neutralization tests. When live DENV1 virus recovered from humans during the acute phase of a dengue infection was used to measure neutralization by antibodies, this virus was neutralized only by homotypic antibodies. By contrast, DENV1 grown in C6/36 or Vero tissue cultures was highly neutralized by homotypic and heterotypic dengue antibodies. Why? DENV1 grown in humans was found to be fully mature and 50- to 700-fold more infectious in cell culture than virus harvested after one passage in C6/36 or Vero cells. Human plasma and cell culture–derived DENV1 virions had identical genome sequences, indicating that differences in the neutralization of virus were attributable to the maturation state¹¹¹. Might DENV maturation status affect biological outcomes of DENV–antibody interactions, such as heterotypic protection or ADE?

Another explanation for Dengvaxia protection failure is that antibodies raised by vaccine may be poorly matched to the specific DENV genotypes in circulation. Two groups found genetic differences in the DENVs recovered during the first 25 months after first dose from placebos or vaccinated children^{112,113}. The DENV4 in the Sanofi vaccine is genotype II. Genotype I (GI) and genotype II (GII) DENVs were both circulating in Asia during the vaccine trial. Both groups found vaccine efficacy to be higher against GII (83%) compared with GI (47%) DENV4s. In fact, Juraska and colleagues demonstrated that variations at three positions on the envelope protein of DENV4

are strongly correlated with vaccine efficacy¹¹². These three amino acid positions map to a region on E protein recognized by strongly neutralizing antibodies in people who have been infected with DENV4¹¹⁴. Indeed, another study recently demonstrated large differences in the ability of sera from naïve subjects who received the National Institutes of Health dengue vaccine (also based on a DENV4 GII envelope) to neutralize different genotypes of DENV4¹¹⁵. When Dengvaxia data were stratified by age, the effect was stronger in younger than older children¹¹². In children 2 to 8 years old, vaccine efficacy against GII viruses was 76.3% whereas efficacy against GI viruses was only 23.9%. In older children (9 to 14 years old), the vaccine was highly efficacious against both GII (89.8%) and GI (85.5%) viruses. The observation that older children who received the Sanofi vaccine were equally protected against DENV4 GI and GII viruses is best explained by the fact that most of these children had immunity to DENVs before vaccination. In this population, the vaccine stimulates strongly cross-neutralizing and cross-protective antibodies analogous to antibodies that develop after natural second DENV infections with a heterologous serotype¹¹⁶. These antibodies, which target conserved epitopes between serotypes, are unlikely to be influenced by subtle differences between genotypes. In people with no pre-existing immunity to DENVs, current vaccination strategies rely on the ability to induce serotype-specific protection. However, Dengvaxia protection is not durable. Indeed, over the period of 5 to 6 years after first dose, children 2 to 8 years old, vaccinated when seronegative, were not protected but neither did they experience enhanced DENV4 disease¹⁰⁵. It is known that Dengvaxia raises DENV4 type-specific neutralizing antibodies in seronegative persons¹¹⁶. Perhaps, early after vaccination, DENV4 GI antibodies circulate at levels that protect against vaccine-matched GII but not the mismatched GI strains.

Another issue is that T-cell immunity may be crucial to durable protection. Studies on dengue-immune humans in Sri Lanka found that multifunctional CD8⁺ T-cell responses were correlated with protection from DENV disease¹¹⁷. Functional CD8⁺ T-cell responses were directed at a distinct pattern of non-structural protein antigens¹¹⁸. There is growing evidence that human T-cell responses directed at epitopes on non-structural proteins contribute importantly to homotypic and heterotypic DENV protective immunity^{118,119}. These observations were extended to human CD4⁺ T cells that are primed by DENV capsid, NS3 and NS5 antigens^{120,121}. CD4⁺ and CD8⁺ T cells raised after a single dose of a tetravalent live-attenuated dengue vaccine were directed to the same repertoire of non-structural protein antigens as T cells from naturally infected humans^{122,123}. A high frequency of CD107a⁺ IFN- γ ⁺ CD8⁺ T cells raised in A 129 mice immunized with DENV2 PDK53 live-attenuated vaccine mediated efficient viral clearance and superior protection against wild-type DENV challenge¹²⁴. Dengvaxia does not present non-structural DENV proteins to the immune system. Might this absence contribute to the ineffective vaccine protection of seronegatives?

TAK 003

In January 2018, the Takeda Pharmaceutical Company (Tokyo, Japan) announced the completion of phase 3 trials for TAK 003^{125–128}. Efficacy and safety data for this vaccine have

not yet been published (<https://www.takeda.com/newsroom/newsreleases/2019/takedas-dengue-vaccine-candidate-meets-primary-endpoint-in-pivotal-phase-3-efficacy-trial/>). The vaccine consists of a live-attenuated DENV2 strain and three chimeric viruses containing the prM and E protein genes of DENV1, 3, and 4 expressed on the backbone of the DENV2 genome^{129,130}. Of these four viruses, one is a successful vaccine candidate, DENV2 16881 PDK 53. This virus achieved exceptionally high rates of seroconversions in seronegative human volunteers with minimal dengue signs or symptoms¹³¹. Attenuating mutations for all four DENVs were identified, and infectious cDNA clones constructed^{132,133}. The vaccine also includes structural DENV1, 3, and 4 proteins expressed on a DENV2 backbone. The developers hope for successful protection against all DENV infection/disease on the basis of the broad neutralizing antibody responses that follow two doses of TAK 003. Publication of clinical data from phase 3 clinical trials is awaited with interest.

Live-attenuated tetravalent dengue vaccine

There is good dengue vaccine news. For nearly 20 years, the National Institute of Allergy and Infectious Diseases and the Johns Hopkins Bloomberg School of Public Health have designed and tested dengue vaccine candidates. Some were attenuated by removing nucleotides from the non-translated region of the dengue genome. A crucial component of this development program was testing monovalent vaccine candidates for immunogenicity and attenuation in seronegative human volunteers¹³⁴. A final product, the live-attenuated tetravalent dengue vaccine (LATV), consists of mutated DENV 1, 3 and 4 and a chimera of structural DENV 2 on a DENV 4 backbone^{135–137}. Following a single dose of LATV, volunteers were solidly protected from viremia, dengue symptoms, or anamnestic antibody responses after challenge with non-parental wild strains of live DENV2 (Tonga 74) or 3 (Sleman 78)¹³⁸ (Dr. Anna Durbin, personal communication, April 4, 2019). That this protection is likely to be of long duration is evidenced by the solid immune response observed to a booster dose of live-attenuated vaccine given 12 months after initial dose¹³⁹. Protection results are complemented by evidence that a single dose of LATV raises monospecific neutralizing antibodies that are conformationally similar to antibodies raised after human infections with wild-type DENVs that correlate with protection^{140–142}. Moreover, the T-cell responses to LATV closely resemble those raised after infections with wild-type DENVs^{122,123}. Finally, LATV contains genes for three of the four DENV NS1 proteins. LATV is in the third year of phase 3 clinical testing in Brazil. The rate of accruing dengue vaccine efficacy data has been delayed because of an 80% reduction of DENV cases following the Zika virus epidemic of 2016–17 in Brazil¹⁴³. The outlook for LATV, based on phase 2 clinical trials in humans, is that a single dose of this vaccine will raise durable and solid protection against dengue infections in both seronegatives and seropositives.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

1. Vasilakis N, Shell EJ, Fokam EB, *et al.*: **Potential of ancestral sylvatic dengue-2 viruses to re-emerge.** *Virology*. 2007; **358**(2): 402–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Pollett S, Melendrez MC, Maljkovic Berry I, *et al.*: **Understanding dengue virus evolution to support epidemic surveillance and counter-measure development.** *Infect Genet Evol*. 2018; **62**: 279–295.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Powell JR, Gloria-Soria A, Kotsakiozi P: **Recent History of *Aedes aegypti*: Vector Genomics and Epidemiology Records.** *BioScience*. 2018; **68**(11): 854–860.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Kraemer MUG, Reiner RC, Brady OJ, *et al.*: **Past and future spread of the arbovirus vectors *Aedes aegypti* and *Aedes albopictus*.** *Nat Microbiol*. 2019; **4**(5): 854–863.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Chen R, Vasilakis N: **Dengue—quo tu et quo vadis?** *Viruses*. 2011; **3**(9): 1562–608.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Vasilakis N, Weaver SC: **The history and evolution of human dengue emergence.** *Adv Virus Res*. 2008; **72**: 1–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Bhatt S, Gething PW, Brady OJ, *et al.*: **The global distribution and burden of dengue.** *Nature*. 2013; **496**(7446): 504–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Brady OJ, Johansson MA, Guerra CA, *et al.*: **Modelling adult *Aedes aegypti* and *Aedes albopictus* survival at different temperatures in laboratory and field settings.** *Parasit Vectors*. 2013; **6**: 351.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Halstead SB: **Pathogenesis of Dengue: Dawn of a New Era [version 1; peer review: 3 approved].** *F1000Res*. 2015; **4**: pii: F1000 Faculty Rev-1353.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Sabin AB: **Research on dengue during World War II.** *Am J Trop Med Hyg*. 1952; **1**(1): 30–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Nimmannitya S, Halstead SB, Cohen SN, *et al.*: **Dengue and chikungunya virus infection in man in Thailand, 1962–1964. I. Observations on hospitalized patients with hemorrhagic fever.** *Am J Trop Med Hyg*. 1969; **18**(6): 954–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Grange L, Simon-Loriere E, Sakuntabhai A, *et al.*: **Epidemiological risk factors associated with high global frequency of inapparent dengue virus infections.** *Front Immunol*. 2014; **5**: 280.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Halstead SB: **Observations related to pathogenesis of dengue hemorrhagic fever. VI. Hypotheses and discussion.** *Yale J Biol Med*. 1970; **42**: 350–62.
[PubMed Abstract](#) | [Free Full Text](#)
14. Halstead SB, Lan NT, Myint TT, *et al.*: **Dengue hemorrhagic fever in infants: research opportunities ignored.** *Emerg Infect Dis*. 2002; **8**(12): 1474–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Chau TN, Quyen NT, Thuy TT, *et al.*: **Dengue in Vietnamese infants—results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity.** *J Infect Dis*. 2008; **198**(4): 516–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
16. Chau TN, Anders KL, Le Lien B, *et al.*: **Clinical and virological features of Dengue in Vietnamese infants.** *PLoS Negl Trop Dis*. 2010; **4**(4): e657.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Clapham H, Cummings DA, Nisalak A, *et al.*: **Epidemiology of Infant Dengue Cases Illuminates Serotype-Specificity in the Interaction between Immunity and Disease, and Changes in Transmission Dynamics.** *PLoS Negl Trop Dis*. 2015; **9**(12): e0004262.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Gibbons RV, Kalanarooj S, Jarman RG, *et al.*: **Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences.** *Am J Trop Med Hyg*. 2007; **77**(5): 910–3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
19. Bhoomiboonchoo P, Nisalak A, Chansatiporn N, *et al.*: **Sequential dengue virus infections detected in active and passive surveillance programs in Thailand, 1994–2010.** *BMC Public Health*. 2015; **15**: 250.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Nisalak A, Lessler JT, Klungthong C, *et al.*: **Forty Years of Dengue Surveillance at a Tertiary Pediatric Hospital in Bangkok, Thailand, 1973–2012.** *Am J Trop Med Hyg*. 2016; **94**(6): 1342–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Yoon IK, Srikiatkachorn A, Hermann L, *et al.*: **Characteristics of mild dengue virus infection in Thai children.** *Am J Trop Med Hyg*. 2013; **89**(6): 1081–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
22. Yoon IK, Rothman AL, Tannitisupawong D, *et al.*: **Underrecognized mildly symptomatic viremic dengue virus infections in rural Thai schools and villages.** *J Infect Dis*. 2012; **206**(3): 389–98.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Anderson KB, Chunsuttiwat S, Nisalak A, *et al.*: **Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study.** *Lancet*. 2007; **369**(9571): 1452–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Buchy P, Vo VL, Bui KT, *et al.*: **Secondary dengue virus type 4 infections in Vietnam.** *Southeast Asian J Trop Med Public Health*. 2005; **36**(1): 178–85.
[PubMed Abstract](#) | [F1000 Recommendation](#)
25. Thai KT, Phuong HL, Thanh Nga TT, *et al.*: **Clinical, epidemiological and virological features of Dengue virus infections in Vietnamese patients presenting to primary care facilities with acute undifferentiated fever.** *J Infect*. 2010; **60**(3): 229–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Vaughn DW, Green S, Kalayanarooj S, *et al.*: **Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.** *J Infect Dis*. 2000; **181**(1): 2–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Gordon A, Kuan G, Mercado JC, *et al.*: **The Nicaraguan pediatric dengue cohort study: incidence of inapparent and symptomatic dengue virus infections, 2004–2010.** *PLoS Negl Trop Dis*. 2013; **7**(9): e2462.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Halstead SB: **Neutralization and antibody-dependent enhancement of dengue viruses.** *Adv Virus Res*. 2003; **60**: 421–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Sangkawibha N, Rojanasuphot S, Ahandrik S, *et al.*: **Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak.** *Am J Epidemiol*. 1984; **120**(5): 653–69.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Guzman MG, Kouri G, Valdes L, *et al.*: **Enhanced severity of secondary dengue 2 infections occurring at an interval of 20 compared with 4 years after dengue 1 infection.** *PAHO Journal of Epidemiology*. 2002; **81**: 223–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Guzman MG, Alvarez A, Vazquez S, *et al.*: **Epidemiological studies on dengue virus type 3 in Playa municipality, Havana, Cuba, 2001–2002.** *Int J Infect Dis*. 2012; **16**(3): e198–e203.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Hubert B, Halstead SB: **Dengue 1 virus and dengue hemorrhagic fever, French Polynesia, 2001.** *Emerg Infect Dis*. 2009; **15**(8): 1265–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Gamble J, Bethell D, Day NP, *et al.*: **Age-related changes in microvascular permeability: a significant factor in the susceptibility of children to shock?** *Clin Sci (Lond)*. 2000; **98**(2): 211–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Anderson KB, Gibbons RV, Cummings DA, *et al.*: **A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand.** *J Infect Dis*. 2014; **209**(3): 360–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
35. Katzelnick LC, Gresh L, Halloran ME, *et al.*: **Antibody-dependent enhancement of severe dengue disease in humans.** *Science*. 2017; **358**(6365): 929–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Salje H, Cummings DAT, Rodriguez-Barraquer I, *et al.*: **Reconstruction of antibody dynamics and infection histories to evaluate dengue risk.** *Nature*. 2018; **557**(7707): 719–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Guzman MG, Alvarez M, Rodriguez-Roche R, *et al.*: **Neutralizing antibodies after infection with dengue 1 virus.** *Emerg Infect Dis*. 2007; **13**(2): 282–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Lau L, Green AM, Balmaseda A, *et al.*: **Antibody avidity following secondary dengue virus type 2 infection across a range of disease severity.** *J Clin Virol*. 2015; **69**: 63–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Trung DT, Thao le TT, Dung NM, *et al.*: **Clinical features of dengue in a large Vietnamese cohort: intrinsically lower platelet counts and greater risk for bleeding in adults than children.** *PLoS Negl Trop Dis*. 2012; **6**(6): e1679.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
40. Xavier-Carvalho C, Cardoso CC, de Souza Kehdy F, *et al.*: **Host genetics and dengue fever.** *Infect Genet Evol*. 2017; **56**: 99–110.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Boonnak K, Dambach KM, Donofrio GC, *et al.*: **Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection.** *J Virol*. 2011; **85**(4): 1671–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
42. Lert-Itthiporn W, Suktitipat B, Grove H, *et al.*: **Validation of genotype imputation in Southeast Asian populations and the effect of single nucleotide polymorphism annotation on imputation outcome.** *BMC Med Genet*. 2018; **19**(1): 23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Oliveira M, Lert-Itthiporn W, Cavadas B, *et al.*: **Joint ancestry and association**

- test indicate two distinct pathogenic pathways involved in classical dengue fever and dengue shock syndrome. *PLoS Negl Trop Dis*. 2018; 12(2): e0006202. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
44. **F** Sierra B, Triska P, Soares P, *et al.*: **OSBPL10, RXRA and lipid metabolism confer African-ancestry protection against dengue haemorrhagic fever in admixed Cubans.** *PLoS Pathog*. 2017; 13(2): e1006220. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 45. WHO: **Dengue: Guidelines for diagnosis, treatment prevention and control.** Geneva: WHO; 2009; [Reference Source](#)
 46. Rosenberger KD, Lum L, Alexander N, *et al.*: **Vascular leakage in dengue--clinical spectrum and influence of parenteral fluid therapy.** *Trop Med Int Health*. 2016; 21(3): 445–53. [PubMed Abstract](#) | [Publisher Full Text](#)
 47. Ellis EM, Sharp TM, Pérez-Padilla J, *et al.*: **Incidence and Risk Factors for Developing Dengue-Associated Hemophagocytic Lymphohistiocytosis in Puerto Rico, 2008 - 2013.** *PLoS Negl Trop Dis*. 2016; 10(8): e0004939. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 48. Giang HTN, Banno K, Minh LHN, *et al.*: **Dengue hemophagocytic syndrome: A systematic review and meta-analysis on epidemiology, clinical signs, outcomes, and risk factors.** *Rev Med Virol*. 2018; 28(6): e2005. [PubMed Abstract](#) | [Publisher Full Text](#)
 49. Wan Jamaludin WF, Periyasamy P, Wan Mat WR, *et al.*: **Dengue infection associated hemophagocytic syndrome: Therapeutic interventions and outcome.** *J Clin Virol*. 2015; 69: 91–5. [PubMed Abstract](#) | [Publisher Full Text](#)
 50. Nguyen TH, Nguyen TH, Vu TT, *et al.*: **Corticosteroids for dengue - why don't they work?** *PLoS Negl Trop Dis*. 2013; 7(12): e2592. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 51. Lum LC, Abdel-Latif Mel-A, Goh AY, *et al.*: **Preventive transfusion in Dengue shock syndrome-is it necessary?** *J Pediatr*. 2003; 143(5): 682–4. [PubMed Abstract](#) | [Publisher Full Text](#)
 52. Whitehorn J, Rodriguez Roche R, Guzman MG, *et al.*: **Prophylactic platelets in dengue: survey responses highlight lack of an evidence base.** *PLoS Negl Trop Dis*. 2012; 6(6): e1716. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 53. Khan Assir MZ, Ahmad F: **Prophylactic platelet transfusion does not reduce risk of clinical bleeding in adults with dengue and thrombocytopenia.** *Evid Based Med*. 2017; 22(6): 225. [PubMed Abstract](#) | [Publisher Full Text](#)
 54. Rajapakse S, de Silva NL, Weeratunga P, *et al.*: **Prophylactic and therapeutic interventions for bleeding in dengue: a systematic review.** *Trans R Soc Trop Med Hyg*. 2017; 111(10): 433–9. [PubMed Abstract](#) | [Publisher Full Text](#)
 55. **F** Lye DC, Archuleta S, Syed-Omar SF, *et al.*: **Prophylactic platelet transfusion plus supportive care versus supportive care alone in adults with dengue and thrombocytopenia: a multicentre, open-label, randomised, superiority trial.** *Lancet*. 2017; 389(10079): 1611–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 56. Yacoub S, Trung TH, Lam PK, *et al.*: **Cardio-haemodynamic assessment and venous lactate in severe dengue: Relationship with recurrent shock and respiratory distress.** *PLoS Negl Trop Dis*. 2017; 11(7): e0005740. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 57. Lam PK, Ngoc TV, Thu Thuy TT, *et al.*: **The value of daily platelet counts for predicting dengue shock syndrome: Results from a prospective observational study of 2301 Vietnamese children with dengue.** *PLoS Negl Trop Dis*. 2017; 11(4): e0005498. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 58. Stoddard ST, Morrison AC, Vazquez-Prokopec GM, *et al.*: **The role of human movement in the transmission of vector-borne pathogens.** *PLoS Negl Trop Dis*. 2009; 3(7): e481. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 59. Stoddard ST, Forshey BM, Morrison AC, *et al.*: **House-to-house human movement drives dengue virus transmission.** *Proc Natl Acad Sci U S A*. 2013; 110(3): 994–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 60. Perkins TA, Paz-Soldan VA, Stoddard ST, *et al.*: **Calling in sick: impacts of fever on intra-urban human mobility.** *Proc Biol Sci*. 2016; 283(1834): pii: 20160390. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 61. Quyen DL, Thanh Le N, Van Anh CT, *et al.*: **Epidemiological, Serological, and Virological Features of Dengue in Nha Trang City, Vietnam.** *Am J Trop Med Hyg*. 2018; 98(2): 402–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 62. Indriani C, Ahmad RA, Wiratama BS, *et al.*: **Baseline Characterization of Dengue Epidemiology in Yogyakarta City, Indonesia, before a Randomized Controlled Trial of *Wolbachia* for Arboviral Disease Control.** *Am J Trop Med Hyg*. 2018; 99(5): 1299–307. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 63. **F** Ten Bosch QA, Clapham HE, Lambrechts L, *et al.*: **Contributions from the silent majority dominate dengue virus transmission.** *PLoS Pathog*. 2018; 14(5): e1006965. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 64. Duong V, Lambrechts L, Paul RE, *et al.*: **Asymptomatic humans transmit dengue virus to mosquitoes.** *Proc Natl Acad Sci U S A*. 2015; 112(47): 14688–93. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 65. **F** España G, Hogue C, Guignard A, *et al.*: **Biased efficacy estimates in phase-III dengue vaccine trials due to heterogeneous exposure and differential detectability of primary infections across trial arms.** *PLoS One*. 2019; 14(1): e0210041. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 66. Ribeiro GS, Kikuti M, Tauro LB, *et al.*: **Does immunity after Zika virus infection cross-protect against dengue?** *Lancet Glob Health*. 2018; 6(2): e140–e141. [PubMed Abstract](#) | [Publisher Full Text](#)
 67. Perez F, Llau A, Gutierrez G, *et al.*: **The decline of dengue in the Americas in 2017: discussion of multiple hypotheses.** *Trop Med Int Health*. 2019; 24(4): 442–53. [PubMed Abstract](#) | [Publisher Full Text](#)
 68. Ribeiro GS, Kikuti M, Tauro LB, *et al.*: **Can Zika virus antibodies cross-protect against dengue virus? - Authors' reply.** *Lancet Glob Health*. 2018; 6(5): e495. [PubMed Abstract](#) | [Publisher Full Text](#)
 69. Halstead SB: **Mosquito-borne haemorrhagic fevers of South and South-East Asia.** *Bull World Health Organ*. 1966; 35(1): 3–15. [PubMed Abstract](#) | [Free Full Text](#)
 70. **F** Salje H, Paul KK, Paul R, *et al.*: **Nationally-representative serostudy of dengue in Bangladesh allows generalizable disease burden estimates.** *eLife*. 2019; 8: pii: e42869. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 71. Monath TP, Vasconcelos PF: **Yellow fever.** *J Clin Virol*. 2015; 64: 160–73. [PubMed Abstract](#) | [Publisher Full Text](#)
 72. Turell MJ, Gozalo AS, Guevara C, *et al.*: **Lack of Evidence of Sylvatic Transmission of Dengue Viruses in the Amazon Rainforest Near Iquitos, Peru.** *Vector Borne Zoonotic Dis*. 2019. [PubMed Abstract](#) | [Publisher Full Text](#)
 73. Halstead SB, Nimmannitya S, Cohen SN: **Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered.** *Yale J Biol Med*. 1970; 42(5): 311–28. [PubMed Abstract](#) | [Free Full Text](#)
 74. Aye KS, Charnkaew K, Win N, *et al.*: **Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar.** *Hum Pathol*. 2014; 45(6): 1221–33. [PubMed Abstract](#) | [Publisher Full Text](#)
 75. Halstead SB: **Pathogenesis of dengue: challenges to molecular biology.** *Science*. 1988; 239(4839): 476–81. [PubMed Abstract](#) | [Publisher Full Text](#)
 76. Libraty DH, Endy TP, Hough HS, *et al.*: **Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections.** *J Infect Dis*. 2002; 185(9): 1213–21. [PubMed Abstract](#) | [Publisher Full Text](#)
 77. **F** Lam PK, Tam DT, Diet TV, *et al.*: **Clinical characteristics of Dengue shock syndrome in Vietnamese children: a 10-year prospective study in a single hospital.** *Clin Infect Dis*. 2013; 57(11): 1577–86. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 78. Halstead SB, Mahalingam S, Marovich MA, *et al.*: **Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes.** *Lancet Infect Dis*. 2010; 10(10): 712–22. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 79. Halstead SB, Shotwell H, Casals J: **Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection.** *J Infect Dis*. 1973; 128(1): 15–22. [PubMed Abstract](#) | [Publisher Full Text](#)
 80. Talarico LB, Bataille JP, Byrne AB, *et al.*: **The Role of Heterotypic DENV-specific CD8⁺ T Lymphocytes in an Immunocompetent Mouse Model of Secondary Dengue Virus Infection.** *EBioMedicine*. 2017; 20: 202–16. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 81. Zellweger RM, Shresta S: **Mouse models to study dengue virus immunology and pathogenesis.** *Front Immunol*. 2014; 5: 151. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 82. **F** Ng JK, Zhang SL, Tan HC, *et al.*: **First experimental *in vivo* model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies.** *PLoS Pathog*. 2014; 10(4): e1004031. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 83. Mongkolsapaya J, Dejnirattisai W, Xu XN, *et al.*: **Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever.** *Nat Med*. 2003; 9(7): 921–7. [PubMed Abstract](#) | [Publisher Full Text](#)
 84. Srikiatkachorn A, Mathew A, Rothman AL: **Immune-mediated cytokine storm and its role in severe dengue.** *Semin Immunopathol*. 2017; 39(5): 563–74. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 85. Lin CF, Lei HY, Shiau AI, *et al.*: **Antibodies from dengue patient sera cross-react with endothelial cells and induce damage.** *J Med Virol*. 2003; 69(1): 82–90. [PubMed Abstract](#) | [Publisher Full Text](#)
 86. Wan SW, Wu-Hsieh BA, Lin YS, *et al.*: **The monocyte-macrophage-mast cell axis in dengue pathogenesis.** *J Biomed Sci*. 2018; 25(1): 77. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 87. Schlesinger JJ, Brandriss MW, Walsh EE: **Protection of mice against dengue**

- 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. *J Gen Virol*. 1987; 68(Pt 3): 853–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
88. **F** Puerta-Guardo H, Glasner DR, Espinosa DA, *et al.*: **Flavivirus NS1 Triggers Tissue-Specific Vascular Endothelial Dysfunction Reflecting Disease Tropism.** *Cell Rep*. 2019; 26(6): 1598–1613.e8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 89. Young PR, Hilditch PA, Bletchly C, *et al.*: **An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients.** *J Clin Microbiol*. 2000; 38(3): 1053–7.
[PubMed Abstract](#) | [Free Full Text](#)
 90. **F** Avirutnan P, Punyadee N, Noisakran S, *et al.*: **Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement.** *J Infect Dis*. 2006; 193(8): 1078–88.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 91. Alcon-LePoder S, Drouet MT, Roux P, *et al.*: **The secreted form of dengue virus nonstructural protein NS1 is endocytosed by hepatocytes and accumulates in late endosomes: implications for viral infectivity.** *J Virol*. 2005; 79(17): 11403–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 92. **F** Lin SW, Chuang YC, Lin YS, *et al.*: **Dengue virus nonstructural protein NS1 binds to prothrombin/thrombin and inhibits prothrombin activation.** *J Infect*. 2012; 64(3): 325–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 93. Chao CH, Wu WC, Lai YC, *et al.*: **Dengue virus nonstructural protein 1 activates platelets via Toll-like receptor 4, leading to thrombocytopenia and hemorrhage.** *PLoS Pathog*. 2019; 15(4): e1007625.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 94. **F** Modhiran N, Watterson D, Muller DA, *et al.*: **Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity.** *Sci Transl Med*. 2015; 7(304): 304ra142.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 95. **F** Beatty PR, Puerta-Guardo H, Killingbeck SS, *et al.*: **Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination.** *Sci Transl Med*. 2015; 7(304): 304ra141.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 96. Puerta-Guardo H, Glasner DR, Harris E: **Dengue Virus NS1 Disrupts the Endothelial Glycocalyx, Leading to Hyperpermeability.** *PLoS Pathog*. 2016; 12(7): e1005738.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 97. Suwanto S, Sasmono RT, Sinto R, *et al.*: **Association of Endothelial Glycocalyx and Tight and Adherens Junctions With Severity of Plasma Leakage in Dengue Infection.** *J Infect Dis*. 2017; 215(6): 992–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 98. Tang TH, Alonso S, Ng LF, *et al.*: **Increased Serum Hyaluronic Acid and Heparan Sulfate in Dengue Fever: Association with Plasma Leakage and Disease Severity.** *Sci Rep*. 2017; 7: 46191.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 99. Glasner DR, Ratnasiri K, Puerta-Guardo H, *et al.*: **Dengue virus NS1 cytokine-independent vascular leak is dependent on endothelial glycocalyx components.** *PLoS Pathog*. 2017; 13(11): e1006673.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 100. **F** Espinosa DA, Beatty PR, Reiner GL, *et al.*: **Cyclic Dinucleotide-Adjuvanted Dengue Virus Nonstructural Protein 1 Induces Protective Antibody and T Cell Responses.** *J Immunol*. 2019; 202(4): 1153–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 101. **F** Friberg H, Beaumier CM, Park S, *et al.*: **Protective versus pathologic pre-exposure cytokine profiles in dengue virus infection.** *PLoS Negl Trop Dis*. 2018; 12(12): e0006975.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 102. **F** Hadinegoro SR, Arredondo-García JL, Capeding MR, *et al.*: **Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.** *N Engl J Med*. 2015; 373(13): 1195–206.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 103. WHO: **Meeting of the Strategic Advisory Group of Experts on immunization, April 2016 – conclusions and recommendations.** *Wkly Epidemiol Rec*. 2016; 91(21): 266–84.
[PubMed Abstract](#)
 104. Nascimento EJM, George JK, Velasco M, *et al.*: **Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus.** *J Virol Methods*. 2018; 257: 48–57.
[PubMed Abstract](#) | [Publisher Full Text](#)
 105. **F** Sridhar S, Luedtke A, Langevin E, *et al.*: **Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.** *N Engl J Med*. 2018; 379(4): 327–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 106. WHO: **Dengue vaccine: WHO position paper - September 2018.** *Wkly Epidemiol Rec*. 2018; 93(36): 457–76.
[Reference Source](#)
 107. **F** Sabchareon A, Wallace D, Sirivichayakul C, *et al.*: **Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.** *Lancet*. 2012; 380(9853): 1559–67.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 108. **F** Capeding MR, Tran NH, Hadinegoro SR, *et al.*: **Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.** *Lancet*. 2014; 384(9951): 1358–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 109. **F** Villar L, Dayan GH, Arredondo-García JL, *et al.*: **Efficacy of a tetravalent dengue vaccine in children in Latin America.** *N Engl J Med*. 2015; 372(2): 113–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 110. Katzelnick LC, Harris E, Participants in the Summit on Dengue Immune Correlates of Protection: **Immune correlates of protection for dengue: State of the art and research agenda.** *Vaccine*. 2017; 35(36): 4659–69.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 111. **F** Raut R, Corbett KS, Tennekoon RN, *et al.*: **Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies.** *Proc Natl Acad Sci U S A*. 2019; 116(1): 227–232.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 112. **F** Juraska M, Magaret CA, Shao J, *et al.*: **Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials.** *Proc Natl Acad Sci U S A*. 2018; 115(36): E8378–E8387.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 113. **F** Rabaa MA, Girerd-Chambaz Y, Duong Thi Hue K, *et al.*: **Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy.** *eLife*. 2017; 6: pii: e24196.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 114. **F** Nivarthi UK, Kose N, Sapparapu G, *et al.*: **Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.** *J Virol*. 2017; 91(5): pii: e02041-16
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 115. **F** Gallichotte EN, Baric TJ, Nivarthi U, *et al.*: **Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization.** *Cell Rep*. 2018; 25(5): 1214–1224.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 116. Henein S, Swanstrom J, Byers AM, *et al.*: **Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.** *J Infect Dis*. 2017; 215(3): 351–358.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 117. Weiskopf D, Bangs DJ, Sidney J, *et al.*: **Dengue virus infection elicits highly polarized CX3CR1⁺ cytotoxic CD4⁺ T cells associated with protective immunity.** *Proc Natl Acad Sci U S A*. 2015; 112(31): E4256–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 118. Weiskopf D, Cerpas C, Angelo MA, *et al.*: **Human CD8⁺ T-Cell Responses Against the 4 Dengue Virus Serotypes Are Associated With Distinct Patterns of Protein Targets.** *J Infect Dis*. 2015; 212(11): 1743–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 119. **F** Elong Ngono A, Chen HW, Tang WW, *et al.*: **Protective Role of Cross-Reactive CD8 T Cells Against Dengue Virus Infection.** *EBioMedicine*. 2016; 13: 284–293.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 120. **F** Grifoni A, Angelo MA, Lopez B, *et al.*: **Global Assessment of Dengue Virus-Specific CD4⁺ T Cell Responses in Dengue-Endemic Areas.** *Front Immunol*. 2017; 8: 1309.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 121. Tian Y, Sette A, Weiskopf D: **Cytotoxic CD4 T Cells: Differentiation, Function, and Application to Dengue Virus Infection.** *Front Immunol*. 2016; 7: 531.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 122. Weiskopf D, Angelo MA, Bangs DJ, *et al.*: **The human CD8⁺ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.** *J Virol*. 2015; 89(1): 120–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 123. Angelo MA, Grifoni A, O'Rourke PH, *et al.*: **Human CD4⁺ T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity.** *J Virol*. 2017; 91(5): pii: e02147-16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 124. **F** Lam JH, Chua YL, Lee PX, *et al.*: **Dengue vaccine-induced CD8⁺ T cell immunity confers protection in the context of enhancing, interfering maternal antibodies.** *JCI Insight*. 2017; 2(24): pii: 94500.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 125. **F** Osorio JE, Huang CY, Kinney RM, *et al.*: **Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.** *Vaccine*. 2011; 29(42): 7251–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 126. Osorio JE, Velez ID, Thomson C, *et al.*: **Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-**

- naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. *Lancet Infect Dis*. 2014; 14(9): 830–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
127. Rupp R, Luckasen GJ, Kirstein JL, *et al.*: Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study. *Vaccine*. 2015; 33(46): 6351–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 128. Osorio JE, Wallace D, Stinchcomb DT: A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. *Expert Rev Vaccines*. 2016; 15(4): 497–508.
[PubMed Abstract](#) | [Publisher Full Text](#)
 129. Huang CY, Butrapet S, Pierro DJ, *et al.*: Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. *J Virol*. 2000; 74(7): 3020–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 130. Huang CY, Kinney RM, Livengood JA, *et al.*: Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). *PLoS Negl Trop Dis*. 2013; 7(5): e2243.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 131. Vaughn DW, Hoke CH Jr, Yoksan S, *et al.*: Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. *Vaccine*. 1996; 14(4): 329–36.
[PubMed Abstract](#) | [Publisher Full Text](#)
 132. Butrapet S, Huang CY, Pierro DJ, *et al.*: Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3. *J Virol*. 2000; 74(7): 3011–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 133. Kinney RM, Butrapet S, Chang GJ, *et al.*: Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. *Virology*. 1997; 230(2): 300–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 134. Durbin AP, Whitehead SS: Next-generation dengue vaccines: novel strategies currently under development. *Viruses*. 2011; 3(10): 1800–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 135. Whitehead SS: Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine? *Expert Rev Vaccines*. 2016; 15(4): 509–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 136. Durbin AP, Kirkpatrick BD, Pierce KK, *et al.*: A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naïve adults: a randomized, double-blind clinical trial. *J Infect Dis*. 2013; 207(6): 957–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 137. Kirkpatrick BD, Durbin AP, Pierce KK, *et al.*: Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naïve Adults. *J Infect Dis*. 2015; 212(5): 702–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 138. Kirkpatrick BD, Whitehead SS, Pierce KK, *et al.*: The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. *Sci Transl Med*. 2016; 8(330): 330ra36.
[PubMed Abstract](#) | [Publisher Full Text](#)
 139. Durbin AP, Kirkpatrick BD, Pierce KK, *et al.*: A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response. *J Infect Dis*. 2016; 214(6): 832–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 140. Smith SA, de Alwis R, Kose N, *et al.*: Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. *J Infect Dis*. 2013; 207(12): 1898–908.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 141. Tsai WY, Durbin A, Tsai JJ, *et al.*: Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies. *J Virol*. 2015; 89(14): 7348–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 142. Swanstrom JA, Nivarthi UK, Patel B, *et al.*: Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines. *J Infect Dis*. 2019; 220(2): 219–27.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 143. Lopes TRR, Silva CS, Pastor AF, *et al.*: Dengue in Brazil in 2017: what happened? *Rev Inst Med Trop Sao Paulo*. 2018; 60: e43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Subhash G Vasudevan**

Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore

Competing Interests: No competing interests were disclosed.

2. **Aravinda M de Silva**

Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research